REGN stock news · Regeneron Pharmaceuticals
Get alerts for REGN
Follow Regeneron Pharmaceuticals (REGN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for REGNOn Friday, 12 health care stocks saw big price changes, with CareDx and Regeneron going up and Acumen dropping.
NeutralRegeneron shares rose, and the article says its Q3 report came out today. It gives no report figures, so the story does not show a change in Regeneron's business outlook.
Regeneron had a great third quarter, earning $20.07 per share and boosting its stock by 11.46%.
Good for REGNRegeneron beat estimates for profit per share and sales, with 3 drugs setting sales records. Eylea faces pricing pressure and competition, but the broad report favors the company.
Regeneron had a great third quarter, earning $20.07 per share and boosting its stock by 11.46%.
Good for REGNRegeneron beat estimates as profit and sales rose, with record sales for 3 key medicines. Price pressure and competition remain, but the results point to a stronger outlook.
Regeneron Pharmaceuticals shared its financial results for the third quarter of 2026.
NeutralRegeneron filed a report announcing quarterly results, but the supplied text gives no sales or profit figures. It does not change the outlook for the company.
TD Cowen raised its price target for Regeneron Pharmaceuticals to $980, up from $960.
Good for REGNTD Cowen raised its target for Regeneron shares from $960 to $980. This is a favorable analyst signal, though the report adds no new company results.
Regeneron says its new drug can effectively stop unwanted bone growth.
Good for REGNRegeneron reported that Pasatru continued to limit abnormal bone growth in adults with a rare bone-forming disease. The results support the drug despite infections that were managed without treatment stops.
Regeneron Pharmaceuticals, Inc. has signed an important deal with Sanofi worth up to $8 billion.
Good for REGNRegeneron will develop 4 antibody medicines with Sanofi, receiving $1.0 billion upfront and possibly $7.0 billion more. The deal favors Regeneron despite shared costs and a $0.18 quarterly profit-per-share cut.
Sanofi is extending its 20-year partnership with Regeneron and promises to invest up to $8 billion.
Good for REGNRegeneron expanded its drug partnership with Sanofi, securing $1 billion upfront and possible later payments. Shared costs and profits temper the benefit, but the deal favors Regeneron.
Regeneron Pharmaceuticals, Inc. says some directors and officers are leaving, while new ones are being chosen and hired.
NeutralRegeneron set 10-year, performance-based awards for its CEO and chief science officer. Tough targets and rising competition leave no clear change to the company’s outlook.
FDA grants approval to Regeneron for Pasatru, a treatment targeting an ultra-rare bone disorder.
NeutralRegeneron Pharmaceuticals has received FDA approval for Pasatru, a groundbreaking treatment for the ultra-rare bone disorder fibrodysplasia ossificans progressiva. This approval is expected to significantly enhance Regeneron's market position and revenue potential, given the severe nature of the condition and the limited treatment options available.
Following his daughter's serious brain hemorrhage, Bill Ackman contributes $400 million in Pershing Square shares to establish a research institute.
NeutralMentioned in the context of brain research, potentially benefiting from advancements in the field.
Sanofi withdraws Dupixent application in Europe following concerns from the European Medicines Agency.
Bad for REGNPotential negative impact on Regeneron's partnership with Sanofi regarding Dupixent's market prospects.